The Protein Chemistry Laboratory Core (PCLC) will serve as the major protein preparation and analysis resource for the Program Project. The laboratory will be responsible for protein preparation, characterization and identification, which will include project-driven proteomics. The PCLC is equipped with a peptide synthesizer, a lyophilizer, and various fast protein liquid chromatography (FPLC), high-performance LC (HPLC) and ultra-performance LC (UPLC) systems encompassing both micro and macro scales. Most importantly, the laboratory has a """"""""proteomics-appropriate"""""""" mass spectrometry (MS) system equipped with ionization modes that will enable sub-picomole analysis of proteins, peptides, and post-translational modifications (PTM) with bio-informatics support. All protein and peptide products will be subjected to stringent characterization by mass spectrometric/proteomic analysis. Surface plasmon resonance (Biacore) analysis is also available that is adaptable to coupling with the on-site mass spectrometers. The primary services provided will be the provision of protein-related tools and reagents such as purified complement system proteins, antibodies, synthetic peptides, and peptide-like synthetic antagonists that interrupt various and specific complement system protein-protein interactions. In addition, the PCLC will perform MS-based analyses of these reagents along with comprehensive sample analysis and high-throughput screening of PTM related to complement/inflammatory processes. All members of the Program Project will be served by the PCLC.
The Protein Chemistry Laboratory Core (PCLC) will provide all of the projects of this proposal with protein and peptide reagents, including proteins and inhibitors of the complement system, an important part of innate immunity. The PCLC will characterize these products to ensure purity and quality and analyze experimental samples from the various projects through mass spectrometric analyses. These activities of the PCLC are vital for each of the projects to ensure efficient, reliable, and cost-effective research.
|Schmidt, Christoph Q; Harder, Markus J; Nichols, Eva-Maria et al. (2016) Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. Immunobiology 221:503-11|
|Blatt, Adam Z; Saggu, Gurpanna; Kulkarni, Koustubh V et al. (2016) Properdin-Mediated C5a Production Enhances Stable Binding of Platelets to Granulocytes in Human Whole Blood. J Immunol 196:4671-80|
|Mastellos, Dimitrios C; Reis, Edimara S; Yancopoulou, Despina et al. (2016) From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology 221:1046-57|
|Hajishengallis, George; Lambris, John D (2016) More than complementing Tolls: complement-Toll-like receptor synergy and crosstalk in innate immunity and inflammation. Immunol Rev 274:233-244|
|Lindorfer, Margaret A; Cook, Erika M; Reis, Edimara S et al. (2016) Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia. Clin Immunol 171:32-35|
|Maekawa, Tomoki; Briones, Ruel A; Resuello, Ranillo R G et al. (2016) Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3. J Clin Periodontol 43:238-49|
|Hajishengallis, George; Hajishengallis, Evlambia; Kajikawa, Tetsuhiro et al. (2016) Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. Semin Immunol 28:285-91|
|Ricklin, Daniel; Reis, Edimara S; Lambris, John D (2016) Complement in disease: a defence system turning offensive. Nat Rev Nephrol 12:383-401|
|Hajishengallis, George; Moutsopoulos, Niki M (2016) Role of bacteria in leukocyte adhesion deficiency-associated periodontitis. Microb Pathog 94:21-6|
|Wang, Junxiang; Wang, Lu; Xiang, Ying et al. (2016) Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40. Clin Immunol 162:37-44|
Showing the most recent 10 out of 186 publications